Any account of the July 2026 peptide vote that stops at the tally is incomplete. The composition of the committee doing the voting became a story in its own right, reported by STAT, NPR, the Washington Post and several law firms tracking the proceeding.
What follows is what was reported, attributed, and including the response from the department involved.
The appointments
On June 29, 2026, the FDA published the names of eight new panelists for the Pharmacy Compounding Advisory Committee. STAT reported that the majority of the new members are involved with businesses that promote and prescribe peptides, and would be weighing in on rule changes that could benefit them.
The appointments came roughly three weeks before the peptide vote. Sheppard Mullin reported the new members were appointed by the Secretary of Health and Human Services, and that most had what could reasonably be considered ties to the peptide industry, including physicians affiliated with practices and companies that actively promote peptide protocols.
Of the twelve committee members, eight were appointed on June 29. Reporting indicates that all but one of those new appointees had financial ties to medical practices or health businesses that sell or administer synthetic peptides.
| Element | What was reported |
|---|---|
| Date announced | June 29, 2026 |
| New members | Eight, seated as temporary voting members |
| Backgrounds cited | Clinical research, neurology, gastroenterology, pain management, patient advocacy |
| Appointing authority | Secretary of Health and Human Services |
| Vote date | July 23–24, 2026 — roughly three weeks later |
Who raised concerns
STAT reported that one of the new panelists is a pharmacist and Tennessee state senator, whose parent is a member of Congress and also a pharmacist, and who had asked the FDA to ease peptide regulation.
STAT quoted Paul Knoepfler, a professor of cell biology and human anatomy at the UC Davis School of Medicine, describing it as concerning that several members of the newly formulated committee appeared to sell unproven offerings including stem cells and peptides, sometimes both.
The Washington Post reported in July that the FDA itself had raised conflict-of-interest concerns ahead of the panel being seated.
The response
NPR reported that a spokesperson for the Department of Health and Human Services pushed back on the criticism, stating that all members underwent the standard ethics and vetting process.
NPR also quoted one panel member, a physician who runs a Pennsylvania-based clinic advertising peptide protocols and hormone optimization, framing the question as one of patient access — a sentiment echoed repeatedly during the public comment sessions.
That argument deserves to be taken seriously on its merits. Clinicians who work with a class of compounds have relevant expertise, and excluding everyone with practical experience would produce a committee that knows less. Advisory panels routinely include people with domain involvement, and disclosure rather than exclusion is the conventional remedy.
The structural question
The tension is not whether experience is valuable — it is. It is that expertise and financial interest arrived together in most of these appointments, on a question where the financial interest points in one direction. Disclosure identifies that; it does not neutralize it.
How the votes actually fell
Sheppard Mullin's analysis found the votes were not randomly distributed. Five members voted in favor of including all seven peptides, and the panel divided along generally consistent lines across every vote — a pattern the firm attributed to the backgrounds and business affiliations of individual panelists, noting that in almost all cases the newly appointed members voted in favor of lifting restrictions.
NPR reported the same pattern.
Set against that: FDA's career scientists recommended against every one of the seven nominations, applying a four-factor framework covering physical and chemical characterization, historical use in compounding, evidence of effectiveness, and safety. Their briefing documents proposed the same conclusion for all seven — do not add.
The committee overrode that position six times.
The political frame
This did not happen in isolation. HHS Secretary Robert F. Kennedy Jr. announced in February 2026 that many Category 2 peptides would be considered for reclassification, confirmed the removal of twelve from Category 2 in April, and has publicly advocated for greater peptide availability.
Orrick, previewing the meeting, wrote that given the composition of the reconstituted committee the most probable outcome was recommendation for some or all of the seven despite FDA staff briefing documents — and that this would represent a significant departure from prior PCAC precedent.
That prediction proved accurate.
What this means for reading the outcome
It does not mean the recommendations are wrong. A committee with industry ties can reach a correct conclusion, and the access argument its members made has genuine force — bringing these compounds inside a regulated system could plausibly produce more oversight than the current gray market provides.
What it does mean is that the vote is weaker evidence about the underlying science than a vote normally would be. When an advisory panel agrees with the agency's own reviewers, that convergence carries information. When it overrides them along lines that track members' business affiliations, the vote tells you less about the evidence and more about the panel.
The decision now sits with the FDA, which must decide what weight to give recommendations its scientists opposed. That is the question worth watching, and it will be answered in the Federal Register rather than in a committee room.
Common questions
No finding of impropriety has been reported. HHS stated that all members underwent the standard ethics and vetting process. The reporting concerns disclosed financial ties and whether they create bias, not procedural violations.
Not under normal practice. Advisory committees routinely include people with domain experience, and disclosure rather than exclusion is the conventional remedy. The concern reported here is that expertise and financial interest coincided for most new appointees on a question where that interest points one way.
The Washington Post reported in July 2026 that the FDA had raised conflict-of-interest concerns ahead of the panel being seated.
Uncommon, and Orrick characterized the likely outcome as a significant departure from prior PCAC precedent. Agency reviewers recommended against all seven nominations and the committee recommended six.
No. The recommendations stand and proceed to the FDA. It does affect how much the vote tells you about the underlying evidence, which is a separate matter from its procedural validity.
Sources
- US Food and Drug Administration. PCAC meeting, July 23–24, 2026. Meeting docket FDA-2026-N-2979; bulk substances docket FDA-2025-N-6895. fda.gov
- McDermott Will & Schulte. “Bulk-list bound? PCAC backs majority of peptides in two-day public meeting.” July 27, 2026.
- Orrick. “FDA Peptide Compounding Vote: What to Watch at the July PCAC Meeting.” July 2026.
- Sheppard Mullin. “Compounded Peptides on the Loose: What the Recent PCAC Meeting Means for Industry.” August 2026.
- STAT News. “New FDA peptide advisers could benefit from their own rulings.” June 29, 2026.
- STAT News. “Fast-growing peptide business faces crucial week at the FDA.” July 23, 2026.
- NPR. “FDA advisers vote to ease peptide restrictions, despite agency concerns.” July 23, 2026.
- The Washington Post. “FDA raised conflict of interest concerns ahead of new peptide panel.” July 17, 2026.